EHA 2023 Update: There's more to come from EHA... - CLL Support
EHA 2023 Update
You need to be a member of this community to see this post.
Read more about...
2 Replies
You need to be a member of this community to see hidden responses.
Not what you're looking for?
You may also like...
News about V+O and Acalabrutinib from EHA
Hi,
The future of CLL therapy we believe will include fixed duration treatments of non-chemo drugs....
YABTKi or Yet Another BTK inhibitor - an A to Z list of Bruton's Tyrosine Kinase Inhibitors and Degraders following ibrutinib's success
I'll admit that YABTKi is not a recognised CLL related acronym, (acronym lists are here...
Treatment-naive or relapsed CLL patients will soon have zanubrutinib/Brukinsa as a treatment option in the EU
The EC approval is based on positive results from two Phase 3 clinical trials: SEQUOIA...
Acalabrutinib Plus Obinutuzumab Prolongs Progression Free Survival Compared to Other Targeted Agents in Chronic Lymphocytic Leukaemia (CLL)
First-line acalabrutinib plus obinutuzumab prolongs progression-free survival (PFS) compared to...
Efficacy and safety of new‑generation BTKis (primarily acalabrutinib and zanubrutinib) in CLL/SLL: a systematic review and meta‑analysis
The meta-analysis of 20 studies on CLL/SLL patients treated with new-generation BTKis was based on...
Related Posts
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
FDA Approves Zanubrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphom
EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor
Zanubrutinib looks promising on all fronts in first interim analysis of ALPINE Trial - Ibrutinib v Zanubrutinib in R/R CLL - report from EHA- Zanubrutinib PFS, ORR Is Superior to Ibrutinib for Relapsed/Refractory CLL/SLL
